Post by Cyclo Therapeutics, A Rafael Company

Our Phase 3 TransportNPC™ study enrolled participants in 13 countries and 27 trial sites. It included participants from under 1 to 68 years of age – a testament to our commitment to enroll and advance our knowledge of Niemann Pick Type C, and the unmet need that exists for this rare and underserved community. https://lnkd.in/eMtWbwiQ